Pages that link to "Q37003270"
Jump to navigation
Jump to search
The following pages link to Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors (Q37003270):
Displaying 30 items.
- Clinical significance of androgen secretion disorders in men with a malignancy. (Q33840617) (← links)
- Sexual dysfunction and infertility as late effects of cancer treatment (Q34604454) (← links)
- Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship (Q37251177) (← links)
- Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors (Q38305809) (← links)
- Cardiovascular prevention in the cancer survivor (Q38338228) (← links)
- Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies (Q38555776) (← links)
- The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer. (Q38611589) (← links)
- Testosterone deficiency in testicular cancer survivors - a systematic review and meta-analysis. (Q38786676) (← links)
- Recent developments in the management of germ cell tumors (Q38984439) (← links)
- Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors (Q39379480) (← links)
- Long-term cardiovascular complications in stage I seminoma patients. (Q40065469) (← links)
- Long-term health effects among testicular cancer survivors (Q40495955) (← links)
- A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention). (Q40978092) (← links)
- Cardiovascular Mortality in Testicular Nonseminomatous Germ Cell Tumors: Does Statistical Significance Imply Clinical Significance? (Q42350172) (← links)
- Reply: 'Comment on Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'. (Q42921917) (← links)
- Comment on 'Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'. (Q42921920) (← links)
- Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study. (Q48069421) (← links)
- Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome (Q48092877) (← links)
- Reproductive hormones and metabolic syndrome in 24 testicular cancer survivors and their biological brothers (Q48299815) (← links)
- Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score (Q51763501) (← links)
- Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. (Q51764443) (← links)
- Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. (Q52607686) (← links)
- Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. (Q55162138) (← links)
- Mechanisms of Aquaporin-Facilitated Cancer Invasion and Metastasis. (Q55265662) (← links)
- Assessment of the awareness and knowledge of cancer survivors regarding the components of metabolic syndrome. (Q55311939) (← links)
- Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review (Q64247543) (← links)
- Testicular germ cell tumours (Q86879831) (← links)
- Risk factors for cardiovascular disease in 5-year survivors of adolescent and young adult cancer: A Danish population-based cohort study (Q91243389) (← links)
- Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome (Q91651350) (← links)
- Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors (Q91996882) (← links)